For the quarter ending 2025-09-30, ZVRA had $6,727K increase in cash & cash equivalents over the period. $4,155K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -544 | 71,608 |
| Stock-based compensation expense | 2,771 | 5,579 |
| Impairment of intangible assets | 0 | 58,710 |
| Inventory obsolescence charge | 0 | 11,681 |
| Income tax expense | -433 | 3,381 |
| Depreciation and amortization expense | 392 | 3,300 |
| Non-cash interest expense | 685 | 1,352 |
| Fair value adjustment related to warrant and cvr liability | 5,506 | -4,127 |
| Accretion on investments | 1,211 | 1,060 |
| Fair value adjustment related to investments | -124 | 5 |
| Consulting fees paid in common stock | 0 | 75 |
| Loss on foreign currency exchange rates | 5 | -131 |
| Gain on sale of prv | 0 | 148,325 |
| Accounts and other receivables | -1,359 | 6,969 |
| Prepaid expenses and other current assets | 3,046 | 296 |
| Inventories | 194 | 586 |
| Operating lease right-of-use assets | -1,274 | 798 |
| Accounts payable and accrued expenses | -4,730 | -11,269 |
| Discount and rebate liabilities | 1,469 | 3,048 |
| Operating lease liabilities | -1,292 | 746 |
| Other liabilities | 2,832 | 1,991 |
| Net cash used in operating activities | 4,709 | -11,823 |
| Purchases of property and equipment | 554 | 312 |
| Disposals of property and equipment | 589 | - |
| Purchases of investments | 65,111 | 157,712 |
| Maturities of investments | 60,500 | 30,500 |
| Proceeds from sale of prv | 0 | 150,000 |
| Net cash provided by (used in) investing activities | -4,576 | 22,476 |
| Proceeds from issuance of debt, net of lender fees | 0 | 0 |
| Payment of third-party debt issuance costs | 0 | 0 |
| Repayment of debt | 0 | 0 |
| Proceeds from issuance of common stock for options exercised | - | 2,947 |
| Proceeds from insurance financing arrangements | 0 | 0 |
| Proceeds from employee stock purchase plan | 0 | 413 |
| Proceeds from issuance of stock | 0 | - |
| Proceeds from issuance of common stock for options exercised or rsus vested | 3,520 | - |
| Proceeds from issuance of common stock for warrants exercised | 5,957 | - |
| Payments of principal on insurance financing arrangements | 0 | 372 |
| Net cash provided by financing activities | 6,530 | 2,988 |
| Effect of exchange rate changes on cash and cash equivalents | 64 | 286 |
| Net increase in cash and cash equivalents | 6,727 | 13,927 |
| Cash and cash equivalents at beginning of period | 33,785 | - |
| Cash and cash equivalents at end of period | 54,439 | - |
ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA)